Interim Results From A Phase Ib/Ii Study Of Pepinemab In Combination With Avelumab In Advanced Nsclc Patients Following Progression On Prior Systemic And/Or Anti-Pdx Therapies

75Background: Despite progress of immune checkpoint therapies, many cases of non-small cell lung cancer (NSCLC) are refractory or acquire resistance to current therapies. Antibody blockade of semap...